164 related articles for article (PubMed ID: 193113)
1. Application of imidazole as a selective inhibitor thromboxane synthetase in human platelets.
Needleman P; Raz A; Ferrendelli JA; Minkes M
Proc Natl Acad Sci U S A; 1977 Apr; 74(4):1716-20. PubMed ID: 193113
[TBL] [Abstract][Full Text] [Related]
2. Cyclic adenosine 3',5'-monophosphate inhibits the availability of arachidonate to prostaglandin synthetase in human platelet suspensions.
Minkes M; Stanford N; Chi MM; Roth GJ; Raz A; Needleman P; Majerus PW
J Clin Invest; 1977 Mar; 59(3):449-54. PubMed ID: 190267
[TBL] [Abstract][Full Text] [Related]
3. Imidazole: a selective inhibitor of thromboxane synthetase.
Moncada S; Bunting S; Mullane K; Thorogood P; Vane JR; Raz A; Needleman P
Prostaglandins; 1977 Apr; 13(4):611-8. PubMed ID: 558637
[TBL] [Abstract][Full Text] [Related]
4. Thromboxane synthetase inhibitors as pharmacological tools: differential biochemical and biological effects on platelet suspensions.
Needleman P; Bryan B; Wyche A; Bronson SD; Eakins K; Ferrendelli JA; Minkes M
Prostaglandins; 1977 Nov; 14(5):897-907. PubMed ID: 594391
[TBL] [Abstract][Full Text] [Related]
5. A comparison of imidazole and 9,11-azoprosta-5,13-dienoic acid. Two selective thromboxane synthetase inhibitors.
Fitzpatrick FA; Gorman RR
Biochim Biophys Acta; 1978 Mar; 539(2):162-72. PubMed ID: 629996
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of thromboxane A2 biosynthesis in human platelets by burimamide.
Allan G; Eakins KE; Kulkarni PS; Levi R
Br J Pharmacol; 1980; 71(1):157-64. PubMed ID: 6781572
[TBL] [Abstract][Full Text] [Related]
7. Effects of thromboxane synthetase inhibition on arachidonate metabolism and platelet behaviour.
Parry MJ
Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):23S-29S. PubMed ID: 6401997
[TBL] [Abstract][Full Text] [Related]
8. Prostaglandin biosynthesis in platelets: demonstration and role of prostaglandin H2 leads to E2 isomerase.
Raz A; Aharony D
Res Commun Chem Pathol Pharmacol; 1978 Sep; 21(3):507-15. PubMed ID: 705027
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of platelet aggregation by 1-alkylimidazole derivatives, thromboxane A synthetase inhibitors.
Kayama N; Sakaguchi K; Kaneko S; Kubota T; Fukuzawa T; Kawamura S; Yoshimoto T; Yamamoto S
Prostaglandins; 1981 Apr; 21(4):543-54. PubMed ID: 7196056
[TBL] [Abstract][Full Text] [Related]
10. 9,11-Iminoepoxyprosta-5,13-dienoic acid is a selective thromboxane A2 synthetase inhibitor.
Fitzpatrick F; Gorman R; Bundy G; Honohan T; McGuire J; Sun F
Biochim Biophys Acta; 1979 May; 573(2):238-44. PubMed ID: 375987
[TBL] [Abstract][Full Text] [Related]
11. Relationship between cyclic AMP and thromboxane formation in platelet-endothelial cell interactions.
Lagarde M; Felisi O; Boukhchache D; Sicard B; Dechavanne M
Thromb Res; 1984 Jul; 35(2):141-7. PubMed ID: 6089369
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of human platelet thromboxane synthetase by 9,11-azoprosta-5,13-dienoic acid.
Gorman RR; Bundy GL; Peterson DC; Sun FF; Miller OV; Fitzpatrick FA
Proc Natl Acad Sci U S A; 1977 Sep; 74(9):4007-11. PubMed ID: 269449
[TBL] [Abstract][Full Text] [Related]
13. Thromboxane synthase inhibition potentiates washed platelet activation by endogenous and exogenous arachidonic acid.
Patscheke H
Biochem Pharmacol; 1985 Apr; 34(8):1151-6. PubMed ID: 3922373
[TBL] [Abstract][Full Text] [Related]
14. Influence of selective thromboxane synthetase blocker CGS-13080 on thromboxane and prostacyclin biosynthesis in whole blood: evidence for synthesis of prostacyclin by leukocytes from platelet-derived endoperoxides.
Mehta J; Mehta P; Lawson DL; Ostrowski N; Brigmon L
J Lab Clin Med; 1985 Sep; 106(3):246-52. PubMed ID: 3928780
[TBL] [Abstract][Full Text] [Related]
15. Platelet and blood vessel arachidonate metabolism and interactions.
Needleman P; Wyche A; Raz A
J Clin Invest; 1979 Feb; 63(2):345-9. PubMed ID: 372240
[TBL] [Abstract][Full Text] [Related]
16. Impairment of platelet thromboxane A2 generation and of the platelet release reaction in two patients with congenital deficiency of platelet cyclo-oxygenase.
Lagarde M; Byron PA; Vargaftig BB; Dechavanne M
Br J Haematol; 1978 Feb; 38(2):251-66. PubMed ID: 205238
[TBL] [Abstract][Full Text] [Related]
17. SQ 22536, an adenylate-cyclase inhibitor, prevents the antiplatelet effect of dazoxiben, a thromboxane-synthetase inhibitor.
Bertelé V; Falanga A; Tomasiak M; Cerletti C; de Gaetano G
Thromb Haemost; 1984 Feb; 51(1):125-8. PubMed ID: 6326343
[TBL] [Abstract][Full Text] [Related]
18. Familial bleeding tendency with partial platelet thromboxane synthetase deficiency: reorientation of cyclic endoperoxide metabolism.
Defreyn G; Machin SJ; Carreras LO; Dauden MV; Chamone DA; Vermylen J
Br J Haematol; 1981 Sep; 49(1):29-41. PubMed ID: 6268139
[TBL] [Abstract][Full Text] [Related]
19. Reorientation of prostaglandin endoperoxide metabolism by a thromboxane synthetase inhibitor: in vitro and clinical observations.
Vermylen J; Deckmyn H
Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):17S-22S. PubMed ID: 6297527
[TBL] [Abstract][Full Text] [Related]
20. Mepacrine blockade of arachidonate-induced washed platelet aggregation: relationship to mepacrine inhibition of platelet cyclooxygenase.
Raz A
Thromb Haemost; 1983 Dec; 50(4):784-6. PubMed ID: 6420923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
